System1 Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
System1 Biosciences, Inc. - overview
Established
2017
Location
San Francisco, CA, US
Primary Industry
Pharmaceuticals
About
System1 Biosciences, Inc. is a biotechnology firm specializing in innovative solutions for drug discovery and development, leveraging advanced technologies for therapeutic advancements. Founded in 2017 in San Francisco, US, System1 Biosciences, Inc. focuses on transforming drug discovery processes.
The company has not undergone any significant pivots. Co-founded by Saul Kato and Sean Escola, it has secured a total of USD 25. 00 mn in funding through a Series A round on August 2, 2018, with investors including CRV and Pfizer Venture Investments. The company maintains its headquarters in San Francisco and has executed one notable deal.
System1 Biosciences, Inc. offers advanced digital solutions for drug discovery, focusing on high-throughput screening and data analytics to support pharmaceutical research. Its services are tailored for biotech and pharmaceutical companies, enabling them to optimize their drug development pipelines. The company's clientele includes research institutions and pharmaceutical entities, with an emphasis on enhancing research efficiency and accuracy in drug testing and validation.
The company generates revenue through a project-based model, charging clients for its specialized services in drug discovery. Clients select service packages based on their specific research needs and project scopes, allowing for a flexible pricing strategy that accommodates various budget levels. System1 Biosciences serves a diverse range of pharmaceutical and biotech companies, establishing ongoing collaborative partnerships that foster sustained revenue generation. System1 Biosciences, Inc.
plans to expand its product offerings with new platforms aimed at integrating artificial intelligence in drug discovery processes, targeting a rollout by late 2023. Geographic expansion into European markets is also on the agenda, aiming for implementation in 2024. The recent Series A funding of USD 25. 00 mn will be utilized to support these initiatives, enhancing technology development and market entry strategies.
Current Investors
CRV, Alexandria Venture Investments, Pfizer Venture Investments
Primary Industry
Pharmaceuticals
Sub Industries
Dermatology, Pharmaceutical Research & Development
Website
www.system1.bio
Company Stage
Series A
Total Amount Raised
Subscriber access only
System1 Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.